Metabolic Disorders News and Research

RSS

Positive results from RXi's sd-rxRNA technology for development of novel therapeutics

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, announced today that, as part of its collaboration with miRagen Therapeutics, positive data were generated demonstrating that RXi's sd-rxRNA technology can be used, in vitro, to specifically enhance the activity of a microRNA of high interest to miRagen.

28 Jan 2011

Lancet series examines health challenges in India

"Indians are growing richer, but they are also adopting unhealthy lifestyles that could take years off their lives and threaten economic growth," according to an article published in Lancet Tuesday, Agence France-Presse reports (1/11). The article is one of seven published in the Lancet as part of a series that also includes a set of commentary pieces on health issues facing the country (1/11).

12 Jan 2011

Neurology professor receives MFRF's 'See the Light' award for Tay-Sachs research

Miguel Sena-Esteves, PhD, associate professor of neurology at the University of Massachusetts Medical School, was presented with the annual "See the Light" award from the Mathew Forbes Romer Foundation in recognition of his work for leading the fight against children's genetic diseases of the brain.

12 Jan 2011

Anchor announces rapid progress in OMJPI collaboration for developing GPCR therapeutic compounds

Anchor Therapeutics today announced that it has successfully completed the first stage of its collaboration and license agreement with Ortho-McNeil-Janssen Pharmaceuticals.

10 Jan 2011

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Isis Pharmaceuticals, announced today that it has added two new drugs to its development pipeline, ISIS-FGFR4Rx and ISIS-STAT3Rx.

7 Jan 2011

Amylin submits metreleptin rolling submission BLA for treatment of rare forms of lipodystrophy

Amylin Pharmaceuticals, Inc. today announced that it has submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy.

21 Dec 2010

Accelerator announces Series A Preferred Stock financing of Acylin

Accelerator Corporation, a privately held, venture capital backed biotechnology investment and development company, announced today the Series A Preferred Stock financing of Acylin Therapeutics, Inc. This is the eleventh company backed by Accelerator and its first investment in intellectual property developed by either Johns Hopkins University School of Medicine or The Wistar Institute, the co-owners of the underlying technology.

1 Dec 2010

Profil Institute expands capabilities to detect cardiac safety signals in diabetes and obesity clinical trials

Profil™ Institute for Clinical Research, Inc., a company specializing in early phase clinical trials for diabetes and obesity, announced today the expansion of its capabilities for cardiac safety and cardiovascular efficacy studies in the company's early phase diabetes and obesity clinical trials.

22 Nov 2010

Stealth Peptides introduces Bendavia clinical candidate at AHA Scientific Sessions

Stealth Peptides, a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with significant unmet medical needs, introduced its lead clinical candidate, Bendavia, a novel compound that targets the mitochondrion, at the 2010 American Heart Association's (AHA) Scientific Sessions, Resuscitation Science Symposium.

22 Nov 2010

Harvard researcher to receive 2010 Naomi Berrie Award from Columbia University Medical Center

Columbia University Medical Center will present the 2010 Naomi Berrie Award to a Harvard researcher who has made important advances in understanding the molecular basis for links between obesity, diabetes and heart disease. A promising young investigator at Columbia will also be recognized for her novel investigations regarding the basis for disordered lipid metabolism in diabetes.

20 Nov 2010

Discovery could provide new approaches to treat metabolic disorders

Scientists from the Florida campus of The Scripps Research Institute have identified a novel synthetic activator of a pair of proteins that belong to a protein family playing key roles in human metabolism and immune function. The discovery could provide new and potentially more effective therapeutic approaches to diseases ranging from diabetes to osteoporosis.

20 Nov 2010

Childhood obesity linked to adult metabolic abnormalities and cardiovascular disease

Mounting evidence linking childhood obesity to an increasing risk of obesity, heart disease, type 2 diabetes, and other cardiovascular and metabolic disorders in adulthood is clearly presented in a comprehensive review article in the current issue of Childhood Obesity, published by Mary Ann Liebert, Inc. The article is available free online.

19 Nov 2010

New cellular pathway could help develop therapeutic treatments for obesity-related disorders

Cardiac researchers at the University of Cincinnati (UC) have found a new cellular pathway that could help in developing therapeutic treatments for obesity-related disorders, like diabetes and heart disease.

17 Nov 2010

Novel mechanism regulating circadian rhythm identified

Scientists from the Florida campus of The Scripps Research Institute have identified for the first time a novel mechanism that regulates circadian rhythm, the master clock that controls the body's natural 24-hour physiological cycle. These new findings could provide a new target not only for jet lag, shift work, and sleep disturbances, but also for disorders that result from circadian rhythm disruption, including diabetes and obesity as well as some types of cancer.

11 Nov 2010

Pleasurable activity also reduces stress by inhibiting anxiety responses

Whether it's food or sex, pleasurable activity provides more than just pleasure, University of Cincinnati (UC) researchers say. It actually reduces stress by inhibiting anxiety responses in the brain.

11 Nov 2010

Colcrys safe for treating gout flares

Patients who experience gout flares can be treated safely with Colcrys (colchicine, USP), even in the presence of co-morbid conditions that often present physicians with treatment challenges, according to a new analysis presented here at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR).

9 Nov 2010

Boehringer Ingelheim announces availability of PRADAXA in U.S. pharmacies

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that its new oral anticoagulant, Pradaxa® (dabigatran etexilate mesylate) 150mg capsules, will be available starting Wednesday by prescription in pharmacies across the United States, including CVS/pharmacy, Rite Aid, Walmart, Target, Kmart® and The Kroger Co. In addition, leading independents under the Health Mart®, Good Neighbor Pharmacy® and Medicine Shoppe® banners will be stocked.

2 Nov 2010

Women with type O blood linked to low egg numbers

In a study presented earlier this week at the American Society of Reproductive Medicine Conference in Denver, researchers at Yale and Albert Einstein College of Medicine measured levels of a chemical called follicle-stimulating hormone (FSH) in 560 women undergoing fertility treatments and found that those women with type O blood had chemical signs linked to low egg numbers.

30 Oct 2010

Metabolon receives patent for biomarkers to determine PPAR-affecting drugs

Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announced today the grant of US Patent 7,807,138 entitled "Biomarkers of Metabolic Responses to Hepatic Drugs". The USPTO awarded the patent to Metabolon on October 5, 2010. This is the 13th patent issued to Metabolon and the second in its portfolio of biomarker patents.

21 Oct 2010

GI Dynamics' EndoBarrier therapy to treat type 2 diabetes and obesity granted European CE mark approval

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier, a non-surgical therapy to treat type 2 diabetes and obesity. This approval is specific to up to 12 months of treatment with the EndoBarrier; the product has already received CE mark approval for three and six months of treatment. Through its commercial partner, Elemental Healthcare, GI Dynamics has also announced the launch of the EndoBarrier in the United Kingdom.

15 Oct 2010